Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $12.0M | $9.03M | $5.12M | $7.57M | $35.6M |
| Revenue growth | — | — | — | — | — | -24.7% | -43.3% | 47.7% | 370.2% |
| Operating income | -$4.46M | -$21.9M | -$30.1M | -$40.2M | -$30.9M | -$21.3M | -$65.8M | -$65.9M | -$12.2M |
| Operating margin | — | — | — | — | -257.6% | -235.8% | -1283.4% | -871.3% | -34.2% |
| Net income | -$4.46M | -$20.6M | -$28.2M | -$42.7M | -$35.1M | -$24.5M | -$67.0M | -$76.6M | -$17.9M |
| Net margin | — | — | — | — | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| EPS (diluted) | -$1.56 | -$1.41 | -$1.13 | -$1.71 | -$1.30 | -$0.72 | -$1.48 | -$14.78 | -$1.68 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.58M | -$17.9M | -$27.4M | -$30.2M | -$27.6M | -$18.6M | -$38.6M | -$60.9M | -$17.6M |
| Capital expenditures | — | $774K | $682K | $1.47M | $883K | $302K | $362K | $27.0K | $0.00 |
| Free cash flow | — | -$18.6M | -$28.1M | -$31.7M | -$28.5M | -$19.0M | -$38.9M | -$61.0M | -$17.6M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.66M | $10.3M | $9.24M | $10.7M | $15.8M | $34.3M | $69.5M | $46.3M | $30.1M |
| Total assets | $9.08M | $91.9M | $68.4M | $74.2M | $80.1M | $44.7M | $81.6M | $54.1M | $47.1M |
| Total liabilities | $616K | $2.48M | $3.41M | $41.2M | $47.5M | $4.69M | $61.8M | $64.0M | $22.4M |
| Long-term debt | — | — | — | — | — | $0.00 | $42.9M | $31.0M | $0.00 |
| Shareholders' equity | -$7.04M | $89.4M | $65.0M | $33.0M | $32.6M | $40.0M | $19.8M | -$9.86M | $24.7M |
| Retained earnings | -$12.4M | -$33.1M | -$61.2M | -$104M | -$139M | -$163M | -$230M | -$307M | -$325M |
| Shares (wtd avg diluted) | 3.70M | 25.7M | 25.8M | 25.4M | 27.0M | 34.2M | 45.3M | 5.18M | 10.7M |
Every figure is extracted from Verrica Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.